161Tb-PSMA-1 (radiopharmaceutical)
Phase 1
161Tb-PSMA-1 (radiopharmaceutical) is one of 7 therapeutic programs targeting Metastatic Clear Cell Renal Cell Carcinoma. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
6
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
6 competitors in Metastatic Clear Cell Renal Cell Carcinoma
#DrugCompanyPhaseTrials
1Cabometyx
Bristol-Myers SquibbPhase 3
Casdatifan
Arcus BiosciencesPhase 3
Tuoyi
CCoherus Oncology, Inc.
Phase 2
Inlyta
PPrism Pharmaceuticals
Phase 2
PD-1
SSichuan Baili Pharmaceutical Co., Ltd.
Phase 2
Welireg
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 1
161Tb-PSMA-1 (radiopharmaceutical)
CCentre Leon Berard
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 1[1]
- Company
- CCentre Leon Berard